Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (DTIL), a clinical-stage biotechnology firm, announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will take place on June 3, 2020, where CEO Matt Kane will speak from 9:30 AM to 9:55 AM ET. Following that, the company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, with Kane speaking from 8:50 AM to 9:30 AM ET. Live webcasts can be accessed on the company’s website, with replays available for 30 days post-presentation.
Summary not available.